{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:34:29Z","timestamp":1791844469461,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"European Commission Seventh Framework Program","award":["HEALTH-F2-2010-242114"],"award-info":[{"award-number":["HEALTH-F2-2010-242114"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Hypothesis<\/jats:title>\n                  <jats:p>This analysis examined the relationship between cannabis use, compliance with antipsychotics and risk for relapse in patients in remission following a first episode of schizophrenia, schizophreniform, or schizoaffective disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design<\/jats:title>\n                  <jats:p>Analyses were performed on data from a large European study on first episode of schizophrenia, schizophreniform, or schizoaffective disorder (OPTiMiSE). After 10 weeks of antipsychotic treatment, 282\/446 patients (63%) met criteria for symptomatic remission; of whom 134\/282 (47.5%) then completed a 1-year follow-up. Cross-lagged models and mediation models investigated the temporal relationships between cannabis use, compliance with antipsychotics, social functioning, and symptomatic worsening\/relapse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Results<\/jats:title>\n                  <jats:p>Compared to nonusers, cannabis use increased risk for relapse, adjusted hazard ratio (HR)\u2005=\u20053.03 (SE\u2005=\u20050.32), P\u2005&amp;lt;\u2005.001, even in patients who were compliant with antipsychotic medication, adjusted HR\u2005=\u20052.89, (SE\u2005=\u20050.32), P\u2005&amp;lt;\u2005.001. Cannabis use preceded symptomatic worsening and was followed by worsening of Positive and Negative Syndrome Scale total score at the 1-year end-point (standardized \u03b2\u2005=\u20050.62, SE\u2005=\u20050.19, P\u2005=\u2005.001) and by worsening of social functioning (coef\u2005=\u2005\u22120.66, P \u2264 .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients in remission from their first episode of schizophrenia, schizophreniform, or schizoaffective disorder, cannabis use increases the rate of relapse in both compliant and noncompliant individuals. Importantly, the temporal relationship between cannabis and relapse was that cannabis use preceded later relapse, noncompliance, and decrease in social functioning, and not that patients began to relapse, then used cannabis. Further research with a precision psychiatry approach might identify those patients in particular danger of relapse when using cannabis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/schbul\/sbad033","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T09:51:10Z","timestamp":1680256270000},"page":"903-913","source":"Crossref","is-referenced-by-count":25,"title":["Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study"],"prefix":"10.1093","volume":"49","author":[{"given":"Linda","family":"Levi","sequence":"first","affiliation":[{"name":"Psychiatry Department, Sheba Medical Center , Ramat Gan , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Bar-Haim","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Sheba Medical Center , Ramat Gan , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Winter-van Rossum","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[{"name":"Nicosia University School of Medicine , Nicosia Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Technical University of Munich , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang W","family":"Fleischhacker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University Innsbruck , Innsbruck , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Psychology and Neuroscience, Duke University , Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Illinois , Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e8 S","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine , Mount Sinai, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weiser","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Sheba Medical Center , Ramat Gan , Israel"},{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"9618","key":"2023070412043012000_CIT0001","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet."},{"issue":"S22","key":"2023070412043012000_CIT0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000292544","article-title":"Understanding the mechanism of action of atypical antipsychotic drugs: a review of compounds in use and development","volume":"163","author":"Lieberman","year":"1993","journal-title":"Br J Psychiatry."},{"issue":"11","key":"2023070412043012000_CIT0003","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","article-title":"Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia","volume":"158","author":"Gitlin","year":"2001","journal-title":"Am J Psychiatry."},{"key":"2023070412043012000_CIT0004","doi-asserted-by":"crossref","first-page":"c4024","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ."},{"issue":"1","key":"2023070412043012000_CIT0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr Res."},{"issue":"3","key":"2023070412043012000_CIT0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch Gen Psychiatry."},{"key":"2023070412043012000_CIT0007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2022.02.026","article-title":"Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia","volume":"243","author":"Bioque","year":"2022","journal-title":"Schizophr Res."},{"issue":"3","key":"2023070412043012000_CIT0008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","article-title":"Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatry."},{"issue":"4","key":"2023070412043012000_CIT0009","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00406-019-01068-z","article-title":"Cannabis use and psychosis: a review of reviews","volume":"270","author":"Hasan","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"8","key":"2023070412043012000_CIT0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2215-0366(17)30233-X","article-title":"Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis","volume":"4","author":"Schoeler","year":"2017","journal-title":"Lancet Psychiatry."},{"key":"2023070412043012000_CIT0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.psychres.2017.05.009","article-title":"Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis","volume":"255","author":"Schoeler","year":"2017","journal-title":"Psychiatry Res."},{"issue":"10","key":"2023070412043012000_CIT0012","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1017\/S0033291717000046","article-title":"Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis","volume":"47","author":"Foglia","year":"2017","journal-title":"Psychol Med."},{"issue":"5","key":"2023070412043012000_CIT0013","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1192\/bjp.bp.107.046375","article-title":"Effects of cannabis use on outcomes of psychotic disorders: systematic review","volume":"193","author":"Zammit","year":"2008","journal-title":"Br J Psychiatry."},{"key":"2023070412043012000_CIT0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2017.06.018","article-title":"Cannabis-associated psychosis: neural substrate and clinical impact","volume":"124","author":"Murray","year":"2017","journal-title":"Neuropharmacology."},{"issue":"4","key":"2023070412043012000_CIT0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archpsyc.1994.03950040017002","article-title":"Cannabis abuse and the course of recent-onset schizophrenic disorders","volume":"51","author":"Linszen","year":"1994","journal-title":"Arch Gen Psychiatry."},{"issue":"2\u20133","key":"2023070412043012000_CIT0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2009.04.018","article-title":"A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia","volume":"113","author":"Miller","year":"2009","journal-title":"Schizophr Res."},{"issue":"3","key":"2023070412043012000_CIT0017","doi-asserted-by":"crossref","first-page":"e009888","DOI":"10.1136\/bmjopen-2015-009888","article-title":"Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study","volume":"6","author":"Patel","year":"2016","journal-title":"BMJ Open."},{"issue":"20","key":"2023070412043012000_CIT0018","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry."},{"issue":"2\u20133","key":"2023070412043012000_CIT0019","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophr Res."},{"issue":"7","key":"2023070412043012000_CIT0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"Am J Psychiatry."},{"issue":"10","key":"2023070412043012000_CIT0021","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry."},{"issue":"3","key":"2023070412043012000_CIT0022","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry."},{"key":"2023070412043012000_CIT0023","article-title":"CGI. Clinical global impressions.","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"2","key":"2023070412043012000_CIT0024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"2023070412043012000_CIT0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.v62n1003","article-title":"The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials","volume":"62","author":"Davis","year":"2001","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"2023070412043012000_CIT0026","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand."},{"issue":"4","key":"2023070412043012000_CIT0027","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF00802014","article-title":"Demographic factors associated with extreme non-compliance in schizophrenia","volume":"29","author":"Sellwood","year":"1994","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"issue":"6","key":"2023070412043012000_CIT0028","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1037\/0033-2909.82.6.887","article-title":"Cross-lagged panel correlation: a test for spuriousness","volume":"82","author":"Kenny","year":"1975","journal-title":"Psychol Bull."},{"issue":"1","key":"2023070412043012000_CIT0029","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1037\/a0038889","article-title":"A critique of the cross-lagged panel model","volume":"20","author":"Hamaker","year":"2015","journal-title":"Psychol Methods."},{"issue":"4","key":"2023070412043012000_CIT0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/add.14511","article-title":"Time since first cannabis use and 12-month prevalence of cannabis use disorder among youth and emerging adults in the United States","volume":"114","author":"Han","year":"2019","journal-title":"Addiction."},{"issue":"11","key":"2023070412043012000_CIT0031","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2016.2427","article-title":"Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study","volume":"73","author":"Schoeler","year":"2016","journal-title":"JAMA Psychiatry."},{"issue":"8","key":"2023070412043012000_CIT0032","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1176\/appi.ajp.2010.09020189","article-title":"Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization","volume":"167","author":"Foti","year":"2010","journal-title":"Am J Psychiatry."},{"key":"2023070412043012000_CIT0033","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fpsyt.2018.00294","article-title":"Cannabis, a significant risk factor for violent behavior in the early phase psychosis. Two patterns of interaction of factors increase the risk of violent behavior: cannabis use disorder and impulsivity; cannabis use disorder, lack of insight and treatment adherence","volume":"9","author":"Moulin","year":"2018","journal-title":"Front Psychiatry."},{"key":"2023070412043012000_CIT0034","first-page":"1","article-title":"Substance use in psychiatric crisis: relationship to violence","volume":"52","author":"Kalk","year":"2020","journal-title":"Psychol Med."},{"key":"2023070412043012000_CIT0035","author":"Beaudoin","year":"2020"},{"issue":"7","key":"2023070412043012000_CIT0036","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1176\/appi.ajp.2020.19101008","article-title":"Association between the use of cannabis and physical violence in youths: a meta-analytical investigation","volume":"177","author":"Dellazizzo","year":"2020","journal-title":"Am J Psychiatry."},{"key":"2023070412043012000_CIT0037","first-page":"437","article-title":"The link between cannabis use and violent behavior in the early phase of psychosis: the potential role of impulsivity","author":"Valerie","year":"2022","journal-title":"Front in Psychiatry."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/49\/4\/903\/50796498\/sbad033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/49\/4\/903\/50796498\/sbad033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T13:50:11Z","timestamp":1688478611000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/49\/4\/903\/7097646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,31]]},"published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbad033","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,3,31]]}}}